115 related articles for article (PubMed ID: 38528728)
21. Probrain natriuretic peptide for assessment of efficacy in heart failure treatment.
Ozkara A; Turgut F; Selcoki Y; Karanfil A; Metin MR; Kanbay M; Tekin O; Akcay A
Adv Ther; 2007; 24(6):1233-9. PubMed ID: 18165205
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
23. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
[TBL] [Abstract][Full Text] [Related]
24. Left atrial minimum volume is more strongly associated with N-terminal pro-B-type natriuretic peptide than the left atrial maximum volume in a community-based sample.
Hedberg P; Selmeryd J; Leppert J; Henriksen E
Int J Cardiovasc Imaging; 2016 Mar; 32(3):417-25. PubMed ID: 26498654
[TBL] [Abstract][Full Text] [Related]
25. Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction.
Zhang Y; Li SY; Xie JJ; Wu Y
Clin Cardiol; 2020 Jun; 43(6):587-593. PubMed ID: 32212277
[TBL] [Abstract][Full Text] [Related]
26. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
[TBL] [Abstract][Full Text] [Related]
27. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Ferreira JP; Verdonschot J; Wang P; Pizard A; Collier T; Ahmed FZ; Brunner-La-Rocca HP; Clark AL; Cosmi F; Cuthbert J; Díez J; Edelmann F; Girerd N; González A; Grojean S; Hazebroek M; Khan J; Latini R; Mamas MA; Mariottoni B; Mujaj B; Pellicori P; Petutschnigg J; Pieske B; Rossignol P; Rouet P; Staessen JA; Cleland JGF; Heymans S; Zannad F;
JACC Heart Fail; 2021 Apr; 9(4):268-277. PubMed ID: 33549556
[TBL] [Abstract][Full Text] [Related]
28. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
[TBL] [Abstract][Full Text] [Related]
29. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
30. Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.
Azzo JD; Dib MJ; Zagkos L; Zhao L; Wang Z; Chang CP; Ebert C; Salman O; Gan S; Zamani P; Cohen JB; van Empel V; Richards AM; Javaheri A; Mann DL; Rietzschel ER; Schafer PH; Seiffert DA; Gill D; Burgess S; Ramirez-Valle F; Gordon DA; Cappola TP; Chirinos JA
Circ Heart Fail; 2024 Feb; 17(2):e011146. PubMed ID: 38299345
[TBL] [Abstract][Full Text] [Related]
31. Predictors of B-type natriuretic peptide and left atrial volume index in patients with preserved left ventricular systolic function: an echocardiographic-catheterization study.
Jaubert MP; Armero S; Bonello L; Nicoud A; Sbragia P; Paganelli F; Arques S
Arch Cardiovasc Dis; 2010 Jan; 103(1):3-9. PubMed ID: 20142114
[TBL] [Abstract][Full Text] [Related]
32. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
[TBL] [Abstract][Full Text] [Related]
33. Relation of left atrial volume to B-type natriuretic peptide levels in patients with stable chronic heart failure.
Barclay JL; Kruszewski K; Croal BL; Cuthbertson BH; Oh JK; Hillis GS
Am J Cardiol; 2006 Jul; 98(1):98-101. PubMed ID: 16784929
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention.
Siva Sankara C; Rajasekhar D; Vanajakshamma V; Praveen Kumar BS; Vamsidhar A
Indian Heart J; 2015; 67(4):318-27. PubMed ID: 26304563
[TBL] [Abstract][Full Text] [Related]
35. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure.
Teramoto K; Tay WT; Tromp J; Ouwerkerk W; Teng TK; Chandramouli C; Liew OW; Chong J; Poppe KK; Lund M; Devlin G; Troughton RW; Doughty RN; Richards AM; Lam CSP
J Am Heart Assoc; 2024 May; 13(9):e032254. PubMed ID: 38639333
[TBL] [Abstract][Full Text] [Related]
37. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
[TBL] [Abstract][Full Text] [Related]
38. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
[TBL] [Abstract][Full Text] [Related]
39. Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
Peterson TE; Landon C; Haberlen SA; Bhondoekhan F; Plankey MW; Palella FJ; Piggott DA; Margolick JB; Brown TT; Post WS; Wu KC
BMC Cardiovasc Disord; 2022 Sep; 22(1):393. PubMed ID: 36057773
[TBL] [Abstract][Full Text] [Related]
40. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Verdonschot JAJ; Ferreira JP; Pellicori P; Brunner-La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Mariottoni B; Petutschnigg J; Rossignol P; Cleland JGF; Zannad F; Heymans SRB;
Cardiovasc Diabetol; 2021 Aug; 20(1):163. PubMed ID: 34372849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
